Alumis reports Q3 revenue $2.07M, consensus $3.14M

“As we continue to advance our pipeline, we are entering an important period for Alumis (ALMS). Our teams have been working diligently, and we are eagerly anticipating key milestones ahead – with topline Phase 3 ONWARD data for envudeucitinib in moderate-to-severe plaque psoriasis expected to be announced early in the first quarter of 2026, followed by topline Phase 2b LUMUS data in systemic lupus erythematosus in the third quarter,” said Martin Babler, President and Chief Executive Officer of Alumis. “These data readouts have the potential to validate envu’s differentiated profile and unlock broader opportunities across immune-mediated diseases-representing meaningful inflection points for both the company and the patients we aim to serve.”